Anni Morsing1,2, Thomas Lund Andersen3,1, Sara E Dahlsgaard-Wallenius4, Malene Grubbe Hildebrandt3,5,6, Allan Johansen3, Mie Holm Vilstrup3, Henrik Petersen3, Oke Gerke3,5, Poul Flemming Høilund-Carlsen3,5. 1. MAgNetic resonance Technology for Response Adapted radiotherapy (MANTRA), Odense University Hospital, Odense, Denmark. 2. Novo Nordisk A/S, Soeborg, Denmark. 3. Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. 4. Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. sarawallenius@hotmail.com. 5. Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 6. Centre for Innovative Medical Technology (CIMT), Odense University Hospital, Odense, Denmark.
Abstract
BACKGROUND: The use of hybrid PET/MRI for clinical staging is growing in several cancer forms and, consequently, PET/MRI has also gained interest in the assessment of non-small cell lung cancer (NSCLC) and lung lesions. However, lung evaluation with PET/MRI is associated with challenges related to technical issues and diagnostic image quality. We, therefore, investigated the published literature on PET/MRI for clinical staging in NSCLC or lung nodule detection specifically addressing diagnostic accuracy and technical issues. METHODS: The data originates from a systematic search performed in PubMed/MEDLINE, Embase, and Cochrane Library on hybrid PET/MRI in patients with cancer for a scoping review published earlier ( https://doi.org/10.1007/s00259-019-04402-8 ). Studies in English and German evaluating the diagnostic performance of hybrid PET/MRI for NSCLC or lung nodule detection in cancer patients were selected. Data reported in peer-reviewed journals without restrictions to year of publication were included. RESULTS: A total of 3138 publications were identified from which 116 published 2012-2018 were included. Of these, nine studies addressed PET/MRI in NSCLC (4) or lung nodule detection (5). Overall, PET/MRI did not provide advantages in preoperative T- and N-staging in NSCLC compared to PET/CT. The data on M-staging were too few for conclusions to be drawn. The lung nodule detection rate of PET/MRI was comparable to that of PET/CT for FDG-avid nodules larger than 10 mm, but the sensitivity of PET/MRI for detection of non-FDG-avid nodules smaller than 5 mm was low. CONCLUSION: PET/MRI did not provide advantages in T- and N-staging of NSCLC compared to PET/CT. PET/MRI had a comparable sensitivity for detection of FDG-avid lung nodules and nodules over 10 mm, but PET/CT yielded a higher detection rate in non FDG-avid lung nodules under 5 mm. With PET/MRI, the overall detection rate for lung nodules in various cancer types remains inferior to that of PET/CT due to the lower diagnostic performance of MRI than CT in the lungs.
BACKGROUND: The use of hybrid PET/MRI for clinical staging is growing in several cancer forms and, consequently, PET/MRI has also gained interest in the assessment of non-small cell lung cancer (NSCLC) and lung lesions. However, lung evaluation with PET/MRI is associated with challenges related to technical issues and diagnostic image quality. We, therefore, investigated the published literature on PET/MRI for clinical staging in NSCLC or lung nodule detection specifically addressing diagnostic accuracy and technical issues. METHODS: The data originates from a systematic search performed in PubMed/MEDLINE, Embase, and Cochrane Library on hybrid PET/MRI in patients with cancer for a scoping review published earlier ( https://doi.org/10.1007/s00259-019-04402-8 ). Studies in English and German evaluating the diagnostic performance of hybrid PET/MRI for NSCLC or lung nodule detection in cancerpatients were selected. Data reported in peer-reviewed journals without restrictions to year of publication were included. RESULTS: A total of 3138 publications were identified from which 116 published 2012-2018 were included. Of these, nine studies addressed PET/MRI in NSCLC (4) or lung nodule detection (5). Overall, PET/MRI did not provide advantages in preoperative T- and N-staging in NSCLC compared to PET/CT. The data on M-staging were too few for conclusions to be drawn. The lung nodule detection rate of PET/MRI was comparable to that of PET/CT for FDG-avid nodules larger than 10 mm, but the sensitivity of PET/MRI for detection of non-FDG-avid nodules smaller than 5 mm was low. CONCLUSION: PET/MRI did not provide advantages in T- and N-staging of NSCLC compared to PET/CT. PET/MRI had a comparable sensitivity for detection of FDG-avid lung nodules and nodules over 10 mm, but PET/CT yielded a higher detection rate in non FDG-avid lung nodules under 5 mm. With PET/MRI, the overall detection rate for lung nodules in various cancer types remains inferior to that of PET/CT due to the lower diagnostic performance of MRI than CT in the lungs.
Authors: Onofrio A Catalano; Bruce R Rosen; Dushyant V Sahani; Peter F Hahn; Alexander R Guimaraes; Mark G Vangel; Emanuele Nicolai; Andrea Soricelli; Marco Salvatore Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Marius E Mayerhoefer; Helmut Prosch; Lucian Beer; Dietmar Tamandl; Thomas Beyer; Christoph Hoeller; Dominik Berzaczy; Markus Raderer; Matthias Preusser; Maximilian Hochmair; Barbara Kiesewetter; Christian Scheuba; Ahmed Ba-Ssalamah; Georgios Karanikas; Julia Kesselbacher; Gerald Prager; Karin Dieckmann; Stephan Polterauer; Michael Weber; Ivo Rausch; Bernhard Brauner; Harald Eidherr; Wolfgang Wadsak; Alexander R Haug Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-13 Impact factor: 9.236
Authors: Lucia Baratto; K Elizabeth Hawk; Lisa States; Jing Qi; Sergios Gatidis; Louise Kiru; Heike E Daldrup-Link Journal: J Nucl Med Date: 2021-10 Impact factor: 10.057
Authors: Aida Steiner; Sara Narva; Irina Rinta-Kiikka; Sakari Hietanen; Johanna Hynninen; Johanna Virtanen Journal: Cancer Imaging Date: 2021-01-22 Impact factor: 3.909